Oak Review
Best for: shoppers who want both compounded semaglutide and tirzepatide on one platform with a transparent flat monthly price
Telehealth provider offering compounded GLP-1 medications (semaglutide and tirzepatide) operated by Oak Longevity Holdings Corp. with prescriptions issued through NVP Medical Group, P.A.
Medium confidence · Last verified 2026-04-30 via WebFetch live pull · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Oak is one of the most affordable GLP-1 options on the market.
Score Breakdown
Drugs Offered
Oak prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Starting | compounded | $80 |
| Starting | compounded | $149 |
✓ Pros
- •Both compounded semaglutide ($130/mo) and tirzepatide ($199/mo) on a single platform
- •$50 off first month with code OAKNEW50
- •LegitScript-certified pharmacy network
- •No video call required for initial approval; flat per-month pricing across all dose strengths
✗ Cons
- •Pharmacy partners are not publicly named on the marketing site (material gap for YMYL disclosure)
- •Operates in 45 states per Terms of Use, but the public state list is gated behind the signup intake
- •No brand-name Wegovy / Zepbound / Mounjaro / Ozempic available — compounded only
- •Fees are non-refundable per Terms of Use; binding arbitration under Delaware law
Ready to start with Oak?
Starting at $80/month. See current pricing and start your free consultation.
Sources & methodology
Our Oak review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Oak
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Oak?
Starting at $80/month. See current pricing and start your free consultation.